Page 27 - Read Online
P. 27

Ethical consideration                               afterwards and then every 3 months following the procedure:
          Ethical approval was obtained from the Local Ethical   full clinical examination, CBC, prothrombin concentration,
          Committee of the Department of Tropical Medicine, Ain   liver function tests, kidney function, AFP and spiral CT
          Shams University. Written informed consent was obtained   of abdomen. Classification of response was conducted
          from all participants. The right to refuse participation was   according to the European Association for the Study of Liver
          emphasized.                                         amendments that take into account the reduction in viable
                                                              tumor volume due to TACE-induced necrosis as follows.
          Patients                                            Complete response (CR): complete disappearance of all
          The study included 50 cases of diagnosed HCC on top of   known disease and no new lesions; partial response (PR):
          chronic liver disease divided into two groups according to   at least 50% reduction in total tumor load of all measurable
          treatment modality. Group 1: 25 HCC patients underwent   lesions; progressive disease (PD): at least 25% increase in
          TACE only as a control group with 10 (40%) patients with   size of one or more measurable lesions or the appearance
          single tumor sizes of 5 cm and 15 (60%) patients with single   of new lesions; stable disease (SD): does not qualify for CR/
          tumor sizes of 5-7 cm. Group 2: 25 HCC patients underwent   PR or PD. [7]
          RFA followed by TACE (RFA-TACE) within 5 days with 14 (56%)
          patients with single tumor sizes of 5 cm and 11 (44%) patients   Radiofrequency ablation was performed percutaneously under
          with single tumor sizes of 5-7 cm.                  ultrasound guidance after general anesthesia. RITA (Mountain
                                                              View, California, USA) and Boston Scientific (Natick,
          All patients fit clinical, biochemical, radiological (ultrasound)   Massachusetts, USA) expandable-type electrodes were
          criteria of chronic liver disease and had positive hepatitis C   used. These electrodes had multiple thin curved monopolar
          virus (HCV) Ab and/or HbsAg. HCC was diagnosed by evidence   electrodes extending from the central cannula (18-14 gauge).
          of high  fetoprotein (AFP) (> 200 ng/mL) and/or presentation   Radiofrequency emanates from each of these hooks, resulting
          of HCC characteristics by triphasic spiral abdominal computed   in increased coagulation. Also Valley Lab (Boulder, Colorado,
          tomography (CT), according to American Association for the   USA) cooled-tip electrodes (17 gauge) were used. These
          Study of Liver Diseases guidelines. [7]             electrodes have two hollow lumens that permit continuous
                                                              internal cooling of the tip. Using percutaneous endovascular
          Inclusion criteria                                  techniques, TACE was performed by selective catheterization
          We included patients with Child-Pugh class A or B   of the hepatic segmental arteries nourishing the lesions, using
          presentations, prothrombin concentrations of > 50%, platelet   either 5-F catheters (Simmons 1 and Cobra; Mallinckrodt, St.
          counts of > 50,000 per mm , and ultrasound detection of   Louis, USA or Hydrophilic Simmons 1 and Cobra; Terumo,
                                  3
          the lesion to be allowed for percutaneous loco-regional   Tokyo, Japan) or 3-F coaxial microcatheters (Tracker 18;
          ablation therapy.                                   Vascular Access System, Target, St. José, USA; SP Catheter;
                                                              Terumo). TACE was used to deliver potent anticancer drugs
          Exclusion criteria                                  directly into tumor-feeding arteries. As a result, tumors were
          Patients with Child-Pugh class C presentations tumors in   exposed to very high drug concentrations, while systemic
          inaccessible sites or close to vital structures, malignant main   exposure was minimized. The cytotoxic lipiodol mixture
          portal vein involvement and/or extrahepatic metastases. All   was prepared by mixing 100 mg adriablastin powder with
          patients were categorized according to the Barcelona-Clinic liver   10 mL of saline, water soluble contrast and 10 mL of oily
          cancer (BCLC) Staging System of HCC pre- and post-treatment   contrast (Lipiodol Ultra-Fluid; Jubilant HollisterStier General
          to evaluate the general condition, performance status of liver   Partnership 16751 Trans-Canada Highway, Kirkland, Quebec,
          functionality, Child-Pugh scores and Okuda stage. [8-11]  Canada) to ensure a homogenous mixture. Embolization was
                                                              done by mixing small pieces of gel foam particles and water
          Procedures                                          soluble contrast.
          All of the enrolled patients were subjected to tests of:
          complete blood count (CBC), alanine transaminase, aspartate   Statistical analysis
          transaminase, serum albumin, serum bilirubin, prothrombin   The collected data were statistically analyzed using the
          time and international normalized ratio (INR), hepatitis   program SPSS (Statistical Package for Social Sciences,
          markers (HCV Ab, HBsAg and HBcAb), AFP, chest X-ray,   software version 18.0, Echosoft Corporation, USA). Data were
          abdominal ultrasonography and abdominal triphasic spiral CT.  expressed as mean ± standard deviation for quantitative
                                                              parametric measures in addition to median percentiles for
          In post-treatment follow-up studies, all patients were   quantitative non-parametric measures and both number and
          subjected to the following evaluation measures 1-month   percentage for categorized data. The following tests were


          20                                                          Hepatoma Research | Volume 1 | Issue 1 | April 15, 2015
   22   23   24   25   26   27   28   29   30   31   32